Risk Stratification and Prognostic Value of Right Ventricular Dysfunction Screening Using Transthoracic Echocardiography in Acute Pulmonary Embolism (RVD-PE)

June 10, 2026 updated by: Safia Khalaf Abdallah, Sohag University
This observational study evaluates right ventricular dysfunction in patients with acute pulmonary embolism using transthoracic echocardiography and assesses its prognostic significance and risk stratification value.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This observational study evaluates right ventricular dysfunction in patients with acute pulmonary embolism using transthoracic echocardiography and assesses its prognostic significance and risk stratification value.

Study Type

Observational

Enrollment (Estimated)

112

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Safiya Khalaf Abdallah, Assistant lecturer
  • Phone Number: 0201090720819
  • Email: olaamer2026@gmail.com

Study Locations

  • Egypt
      • Sohag, Egypt
        • Recruiting
        • Sohag university Hospital
        • Contact:
        • Principal Investigator:
          • Safiya Khalaf Abdallah, Assistant lecturer
      • Sohag, Egypt
        • Not yet recruiting
        • Sohag university Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Patients diagnosed as acute pulmonary embolism

Description

Inclusion Criteria:

  • Patients aged 18 years and older.
  • Patients with a confirmed diagnosis of acute pulmonary embolism.
  • Patients who underwent transthoracic echocardiographic assessment for right ventricular dysfunction.

Exclusion Criteria:

  • Patients younger than 18 years.
  • Patients with incomplete clinical data.
  • Patients who did not undergo transthoracic echocardiography.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients with acute pulmonary embolism
Patients diagnosed with acute pulmonary embolism who undergo transthoracic echocardiographic assessment for evaluation of right ventricular dysfunction.
Other: Transthoracic Echocardiography
Transthoracic echocardiography performed for assessment of right ventricular dysfunction in patients with acute pulmonary embolism.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Right ventricular dysfunction as a prognostic marker in acute pulmonary embolism
Time Frame: From hospital admission until hospital discharge, with an average duration of 7 days.
To assess the prognostic value of right ventricular dysfunction detected by transthoracic echocardiography for risk stratification in patients with acute pulmonary embolism
From hospital admission until hospital discharge, with an average duration of 7 days.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
In-hospital adverse clinical outcomes
Time Frame: From hospital admission until hospital discharge, with an average duration of 7 days.
To evaluate the occurrence of in-hospital adverse clinical outcomes, including respiratory failure, hemodynamic instability, cardiac arrhythmias, intensive care unit admission, and mortality, and their association with right ventricular dysfunction in patients with acute pulmonary embolism
From hospital admission until hospital discharge, with an average duration of 7 days.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2026

Primary Completion (Estimated)

November 30, 2026

Study Completion (Estimated)

November 30, 2026

Study Registration Dates

First Submitted

May 23, 2026

First Submitted That Met QC Criteria

June 10, 2026

First Posted (Actual)

June 15, 2026

Study Record Updates

Last Update Posted (Actual)

June 15, 2026

Last Update Submitted That Met QC Criteria

June 10, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PE-RVD-2026-01...PE.RVD..2026.

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Individual participants data sharing plans are currently undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pulmonary Embolism

Clinical Trials on Transthoracic Echocardiography

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe